ResMed Inc. Reports Strong Q4 Earnings but Faces Market Pullback
ResMed Inc. (NYSE: RMD), a leading manufacturer of medical equipment for sleep‑disordered breathing, announced its fourth‑quarter and full‑year 2026 results on August 6, 2026. The company delivered a solid earnings performance and raised its dividend, yet its shares slipped roughly 6 % on the day following the announcement.
Financial Highlights
| Metric | Q4 2026 | YoY | Notes |
|---|---|---|---|
| Revenue | $1.463 B | +8.6 % | 9 % growth in the quarter, 8 % on a constant‑currency basis |
| GAAP EPS | $2.64 | +2 % | Slight beat over analyst consensus |
| Non‑GAAP EPS | $2.95 | +16 % | Adjusted earnings highlight strong operating profitability |
| Dividend | $0.66 per share | +10 % | New dividend increases payout to shareholders |
| Shareholder returns | $1.0 B | +70 % | Includes share repurchases and dividends over FY2026 |
The company’s adjusted earnings of $428.3 million ($2.95 per share) surpassed last‑year figures of $379.7 million ($2.58 per share). ResMed’s 52‑week high remains $293.81, while the current close price sits at $211.94, reflecting a market cap of approximately $32.5 billion and a price‑earnings ratio of 21.6.
Guidance for Fiscal 2027
Despite the Q4 success, ResMed’s forward guidance for fiscal 2027 tempered enthusiasm. The company projected revenue of $5.75 B to $5.85 B, below Wall Street expectations. The guidance was driven by:
- Suspension of Astral Ventilator Sales – After a device‑correction issue, ResMed halted sales of its Astral ventilators, which serve patients requiring acute or long‑term life‑support. The pause removed a significant revenue stream from the company’s product portfolio.
- Cost Pressures – Rising manufacturing and supply‑chain costs weighed on gross margins, limiting the upside that analysts had anticipated.
- Regulatory and Market Dynamics – Ongoing scrutiny from the FDA and competitive pressure in the sleep‑disorder market contributed to a more cautious outlook.
The company reaffirmed its non‑GAAP earnings per share guidance of $12 to $12.25 for FY2027 and reaffirmed its commitment to accelerate shareholder returns, targeting $1.85 B+ in dividends and share buybacks over the next few years.
Market Reaction
Shares of ResMed fell about 6 % in early trading on August 7, 2026. Investors reacted to the divergence between solid quarterly results and a more conservative fiscal‑year forecast. Analysts noted that the market had already priced in the earnings beat and dividend increase; the surprise was the downward revenue guidance and the suspension of a key product line.
While the company’s fundamentals remain strong—with robust cash generation, a high‑quality product suite, and a sizeable shareholder‑return program—market sentiment underscored the importance of forward guidance in the medtech sector. The company’s recent actions signal a cautious yet strategic approach to growth, balancing immediate operational challenges with long‑term shareholder value.
Outlook
- Product Portfolio: ResMed will continue to focus on its core sleep‑disorder devices and expand its diagnostics and remote monitoring capabilities.
- Financial Discipline: Management is targeting margin improvement and cost containment while sustaining a high dividend payout.
- Shareholder Returns: The company will maintain a disciplined approach to dividends and share buybacks, aiming to deliver a total return of around 10 % annually.
Investors will likely keep a close eye on subsequent quarterly releases to assess whether ResMed can translate its product innovations into the revenue growth it projected for 2027, while navigating the evolving regulatory and competitive landscape in the medical‑device market.
